Davis R M Inc Amgen Inc Transaction History

Davis R M Inc

$5.31 Billion
Q2 2025

A detailed history of Davis R M Inc transactions in Amgen Inc stock. As of the latest transaction made, Davis R M Inc holds 3,182 shares of AMGN stock, worth $929,144. This represents 0.02% of its overall portfolio holdings.

Number of Shares

3,182

Previous 3,110 2.32%

Holding current value

$929,144

Previous $968,000 8.26%

% of portfolio

0.02%

Previous 0.02%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 07, 2025	BUY	$262.28 - $309.85 $18,884 - $22,309	72 Added 2.32%	3,182 $888,000
Q1 2025 May 08, 2025	SELL	$258.59 - $327.36 $55,338 - $70,055	-214 Reduced 6.44%	3,110 $968,000
Q4 2024 Feb 07, 2025	SELL	$258.78 - $328.31 $38,558 - $48,918	-149 Reduced 4.29%	3,324 $866,000
Q3 2024 Nov 12, 2024	SELL	$309.38 - $337.38 $138,602 - $151,146	-448 Reduced 11.43%	3,473 $1.12 Million
Q2 2024 Aug 09, 2024	SELL	$262.75 - $319.31 $38,098 - $46,299	-145 Reduced 3.57%	3,921 $1.23 Million
Q1 2024 May 10, 2024	SELL	$268.87 - $324.56 $11,830 - $14,280	-44 Reduced 1.07%	4,066 $1.16 Million
Q4 2023 Feb 09, 2024	SELL	$255.7 - $288.46 $106,115 - $119,710	-415 Reduced 9.17%	4,110 $1.18 Million
Q3 2023 Nov 14, 2023	SELL	$218.65 - $271.46 $39,357 - $48,862	-180 Reduced 3.83%	4,525 $1.22 Million
Q2 2023 Aug 10, 2023	SELL	$214.27 - $253.37 $138,204 - $163,423	-645 Reduced 12.06%	4,705 $1.05 Million
Q1 2023 May 01, 2023	SELL	$225.79 - $275.2 $54,866 - $66,873	-243 Reduced 4.34%	5,350 $1.29 Million
Q4 2022 Feb 14, 2023	BUY	$229.03 - $291.01 $71,457 - $90,795	312 Added 5.91%	5,593 $1.47 Million
Q3 2022 Nov 08, 2022	SELL	$224.46 - $253.15 $22,446 - $25,315	-100 Reduced 1.86%	5,281 $1.19 Million
Q2 2022 Aug 08, 2022	SELL	$230.71 - $256.74 $76,365 - $84,980	-331 Reduced 5.79%	5,381 $1.31 Million
Q1 2022 May 05, 2022	SELL	$219.27 - $242.57 $102,837 - $113,765	-469 Reduced 7.59%	5,712 $1.38 Million
Q4 2021 Feb 08, 2022	BUY	$198.88 - $227.6 $44,350 - $50,754	223 Added 3.74%	6,181 $1.39 Million
Q3 2021 Nov 08, 2021	SELL	$212.27 - $248.7 $111,866 - $131,064	-527 Reduced 8.13%	5,958 $1.27 Million
Q2 2021 Aug 12, 2021	SELL	$233.58 - $259.14 $58,395 - $64,785	-250 Reduced 3.71%	6,485 $1.58 Million
Q1 2021 May 10, 2021	SELL	$221.91 - $258.6 $40,165 - $46,806	-181 Reduced 2.62%	6,735 $1.68 Million
Q4 2020 Jan 27, 2021	BUY	$216.38 - $257.67 $25,749 - $30,662	119 Added 1.75%	6,916 $1.59 Million
Q3 2020 Dec 01, 2020	SELL	$234.65 - $260.95 $113,101 - $125,777	-482 Reduced 6.62%	6,797 $1.73 Million
Q2 2020 Jul 20, 2020	SELL	$197.81 - $242.74 $58,551 - $71,851	-296 Reduced 3.91%	7,279 $1.72 Million
Q1 2020 Apr 24, 2020	BUY	$182.24 - $241.7 $46,106 - $61,150	253 Added 3.46%	7,575 $1.54 Million
Q4 2019 Jan 23, 2020	BUY	$189.21 - $243.2 $73,035 - $93,875	386 Added 5.57%	7,322 $1.77 Million
Q3 2019 Oct 24, 2019	BUY	$174.11 - $208.62 $111,082 - $133,099	638 Added 10.13%	6,936 $1.34 Million
Q2 2019 Jul 31, 2019	BUY	$166.7 - $195.41 $34,173 - $40,059	205 Added 3.36%	6,298 $1.16 Million
Q1 2019 Apr 29, 2019	SELL	$180.87 - $203.88 $100,201 - $112,949	-554 Reduced 8.33%	6,093 $1.16 Million
Q4 2018 Jan 18, 2019	BUY	$178.4 - $208.25 $72,430 - $84,549	406 Added 6.51%	6,647 $1.29 Million
Q3 2018 Oct 17, 2018	BUY	$185.29 - $208.89 $926 - $1,044	5 Added 0.08%	6,241 $1.29 Million
Q2 2018 Jul 19, 2018	BUY	$166.05 - $186.51 $7,970 - $8,952	48 Added 0.78%	6,236 $1.15 Million
Q1 2018 Apr 19, 2018	SELL	$169.43 - $198.0 $5,421 - $6,336	-32 Reduced 0.51%	6,188 $1.06 Million
Q4 2017 Jan 16, 2018	BUY	$168.79 - $188.59 $9,452 - $10,561	56 Added 0.91%	6,220 $1.08 Million
Q3 2017 Oct 24, 2017	BUY	$167.29 - $191.0 $1.03 Million - $1.18 Million	6,164	6,164 $1.15 Million

Others Institutions Holding AMGN

# of Institutions

3,285

Shares Held

440M

Call Options Held

6.25M

Put Options Held

7.38M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $156B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Davis R M Inc, based on Form 13F filings with the SEC.

News

Stay updated on Davis R M Inc with notifications on news.

Account